An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions - PubMed
4 hours ago
- #multiple myeloma
- #elranatamab
- #bispecific antibody
- Elranatamab is a bispecific antibody targeting BCMA and CD3, approved for relapsed/refractory multiple myeloma.
- Clinical trials show elranatamab has manageable safety and encouraging efficacy in relapsed/refractory multiple myeloma.
- The toxicity profile of elranatamab is comparable to other BCMA-targeting bispecific antibodies.
- Low-grade cytokine release syndrome (CRS) allows outpatient administration of elranatamab.
- High infection rates remain a challenge, but adjustments in prophylaxis and dosing may reduce risks.
- Ongoing trials are exploring elranatamab in first-line treatment and combination regimens, balancing efficacy and toxicity.